UK Markets closed
  • FTSE 100

    +26.32 (+0.37%)
  • FTSE 250

    +123.85 (+0.54%)
  • AIM

    +4.02 (+0.33%)

    +0.0063 (+0.53%)

    +0.0074 (+0.5418%)

    +2,854.98 (+6.84%)
  • CMC Crypto 200

    +57.32 (+4.07%)
  • S&P 500

    +33.11 (+0.75%)
  • DOW

    +382.20 (+1.09%)

    -29.80 (-1.66%)
  • NIKKEI 225

    +517.70 (+1.81%)

    +368.37 (+1.48%)
  • DAX

    +124.64 (+0.81%)
  • CAC 40

    +42.31 (+0.63%)

The Razin Group Issues Presentation Detailing the Need to Reset the Balance of Power in NextGen Healthcare’s Dysfunctional and Insular Boardroom

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Highlights the Company’s Anti-Shareholder Governance, Failed Acquisitions Strategy, Poor Operating Results and Persistent Share Price Underperformance During the Six-Year Chairmanship of Jeffrey Margolis

Outlines the Onerous Terms of the Company’s Proposed Delaware Reincorporation, Which Would Strengthen the Margolis Board’s Power and Weaken Shareholders’ Rights

Opposes the Reelection of Mr. Margolis and Three Entrenched Directors, Who Have Each Held Committee Chair Roles During a Lengthy Period of Stagnation and Underperformance

Urges Shareholders to Vote on the BLUE Proxy Card to Elect the Razin Group’s Minority Slate, Which Possesses a Vision for Improving Governance and Prioritizing Value Creation

IRVINE, Calif., September 24, 2021--(BUSINESS WIRE)--Sheldon Razin, who collectively with Lance Rosenzweig and the other participants in his solicitation (collectively, the "Razin Group") owns approximately 15.2% of the outstanding common shares of NextGen Healthcare, Inc. (NASDAQ: NXGN) ("NextGen Healthcare" or the "Company"), today issued a 70-page presentation that details the case for resetting the balance of power on NextGen Healthcare's nine-member Board of Directors (the "Board"). The Razin Group urges shareholders to vote on the BLUE Proxy Card to elect its four-member slate, which includes Kenneth H. Fearn, Messrs. Razin and Rosenzweig and Ruby Sharma. Please visit to download the Razin Group slate’s presentation and obtain important information about our value-enhancing vision.

Messrs. Razin and Rosenzweig commented:

"This election contest is about resetting the balance of power in NextGen Healthcare's dysfunctional and insular boardroom in order to ensure that shareholders' best interests are prioritized following six years of anemic revenue growth, deteriorating earnings, dismal capital allocation, poor governance and sustained share price underperformance. We contend that the Company has taken a massive step backward during the past six years under the reign of Chairman Jeffrey Margolis and his fellow Board leaders, Craig Barbarosh, George Bristol and Morris Panner. Their consistent disregard for the Company’s shareholders was mostly recently evidenced by the decision to propose an onerous Delaware reincorporation that would strengthen the Margolis Board’s power while taking away shareholders’ rights, such as the right to fill director vacancies and the right to act by written consent. We believe our minority slate possesses the constructive mindset and relevant skills needed to work with the remaining incumbents to fix the Company's troubling governance, non-accretive capital allocation policy and failed execution against growth objectives. In our view, the Company’s shareholders have a unique opportunity this year to establish a new culture of accountability, incentivization and innovation as a new CEO joins – to be clear, NextGen Healthcare’s new leadership should not be continuously beholden to Mr. Margolis and his allies."

View source version on


Harkins Kovler
Jordan Kovler / Rahsaan Wareham, 212-468-5380 /

Greg Marose / Bela Kirpalani, 646-386-0091 /

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting